Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

of metastatic HRPC in combination with full-dose docetaxel (Taxotere(R)) and prednisone. The Company continues to expect to fully enroll this trial by the end of 2007. The Company expects to present clinical data from the Phase 1 and Phase 2 HRPC trials at scientific meetings throughout 2008.

Phase 1 Oral Picoplatin Trial:

An oral formulation of picoplatin is being evaluated in an ongoing Phase 1 clinical trial in solid tumors. Poniard has completed the planned enrollment of the planned dose levels and has expanded the enrollment to include additional testing of various dose levels to provide additional data to support further development. This Phase 1 study compares the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in patients with advanced solid tumor malignancies. The company plans to present data from the Phase 1 trial at scientific meetings in 2008.

Lazard Presentation and Webcast Information

Dr. McMahon will present at the Lazard Capital Markets Fourth Annual Healthcare Conference today at 9:30 a.m. Eastern Time at The New York Palace Hotel. A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. Picoplatin has an improved safety profile compared to existing platinum-based chemotherapeutics and was designed to overcome platinum resistance. Picoplatin has been evaluated in more than 750 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity and hearing loss. The Company is evaluating picoplatin in four dif
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... 11 Chimerix, Inc., a,biotechnology company developing orally ... initiated a multi-dose trial with its,lead drug candidate, ... will study the pharmacokinetics and safety of three ... "The high oral availability demonstrated by CMX001 in ...
... works with hospitals to help reduce spread of ... national forum on quality in,health care, Highmark officials ... designed to deal with Methicillin,Resistant Staphylococcus Aureus (MRSA). ... hospitals in western,Pennsylvania in identifying patients that have ...
Cached Medicine Technology:Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection 2Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference 2
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... of Medicine (BUSM) have discovered that the anti-seizure ... model. The findings, reported in the American ... lead to more effective treatments for alcoholism. , ... leading causes of illness and death in the ... limiting the productivity of workers and necessitating huge ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... one of the important secondary infections among AIDS patients. ... of cases of tuberculosis in England, Wales and Northern ... has topped 7,000 a year. , The ... to enable better identification of the different strains of ...
... has probably acquired a misleading connotation, being prominently associated ... by acute job stress, according to a recent academic ... indicated a group of symptoms that manifested as problems ... tract, all of which was thought of as an ...
... by the St George's Hospital, Stafford, people who self-harm are ... cut themselves, but are also offered alternatives like holding ice ... a duty of care, but there is a difference between ... Holley, who is running the St George's project. People who ...
... have successfully identified a molecule, which could be deployed as ... findings of the study, which is so far based on ... Nature Medicine. Researchers at KI and Leiden University Medical Centre ... we've only conducted research on mice, so it's too early ...
... people turn for help towards chiropractors and osteopaths to treat ... manipulation// is of no or little help to solve these ... Peninsula Medical School in Devon. The results are published in ... team said that the data gave little evidence of effectiveness. ...
... donated by Cuba to help Pakistan recover from the ... lives, in October last year//. ,'Two more ... donated to the government of Pakistan-administered Kashmir,' Col. Muhammad ... Foreign Affairs Bruno Rodriguez Parrilla signed an agreement in ...
Cached Medicine News:Health News:Job Stress, causes build up of ‘Sick building Syndrome 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: